21.45
price down icon2.01%   -0.44
after-market After Hours: 21.45
loading
Arrivent Biopharma Inc stock is traded at $21.45, with a volume of 185.69K. It is down -2.01% in the last 24 hours and down -7.18% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$21.89
Open:
$21.84
24h Volume:
185.69K
Relative Volume:
0.58
Market Cap:
$733.86M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-8.177
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
-5.59%
1M Performance:
-7.18%
6M Performance:
-21.43%
1Y Performance:
+4.58%
1-Day Range:
Value
$20.81
$22.29
1-Week Range:
Value
$20.81
$23.38
52-Week Range:
Value
$15.47
$36.37

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name
Name
Arrivent Biopharma Inc
Name
Phone
240-780-6356
Name
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Name
Employee
52
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
AVBP's Discussions on Twitter

Compare AVBP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AVBP
Arrivent Biopharma Inc
21.45 791.15M 0 -81.05M -68.97M -2.6232
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Goldman Buy
Mar-20-25 Initiated B. Riley Securities Buy
Mar-10-25 Initiated Guggenheim Buy
Jul-22-24 Initiated Oppenheimer Outperform
Apr-30-24 Initiated H.C. Wainwright Buy
Feb-20-24 Initiated Citigroup Buy
Feb-20-24 Initiated Goldman Buy
Feb-20-24 Initiated Jefferies Buy
View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

pulisher
07:20 AM

What analysts say about ArriVent BioPharma Inc. stockExplosive returns - PrintWeekIndia

07:20 AM
pulisher
06:47 AM

What risks could impact ArriVent BioPharma Inc. stock performanceTriple-digit returns - jammulinksnews.com

06:47 AM
pulisher
03:50 AM

Is ArriVent BioPharma Inc. a good long term investmentPowerful market insights - Autocar Professional

03:50 AM
pulisher
03:12 AM

ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MSN

03:12 AM
pulisher
Jul 23, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of “Buy” from Analysts - Defense World

Jul 23, 2025
pulisher
Jul 23, 2025

ArriVent BioPharma Inc. Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada

Jul 22, 2025
pulisher
Jul 22, 2025

What drives ArriVent BioPharma Inc. stock priceAccelerated wealth expansion - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What makes ArriVent BioPharma Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

ArriVent Biopharma announces data from its FURVENT Phase 3 study - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

ArriVent expects topline data from lung cancer drug trial in early 2026 By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

ArriVent expects topline data from lung cancer drug trial in early 2026 - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - The Manila Times

Jul 21, 2025
pulisher
Jul 21, 2025

New Strong Sell Stocks For July 21st - Barchart.com

Jul 21, 2025
pulisher
Jul 21, 2025

New Strong Sell Stocks for July 21st - The Globe and Mail

Jul 21, 2025
pulisher
Jul 18, 2025

Is ArriVent BioPharma Inc. stock a growth or value playDaily Price Surge List - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

P 500Low Risk Trade Timing Signals - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest

Jul 16, 2025
pulisher
Jul 15, 2025

Why ArriVent BioPharma Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

ArriVent BioPharma Conducts $75 Million Public Offering - Global Legal Chronicle

Jul 14, 2025
pulisher
Jul 12, 2025

ArriVent BioPharma (NASDAQ:AVBP) Given a $33.00 Price Target by The Goldman Sachs Group Analysts - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

The Goldman Sachs Group Reiterates “Buy” Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World

Jul 12, 2025
pulisher
Jul 10, 2025

How To Trade (AVBP) - news.stocktradersdaily.com

Jul 10, 2025
pulisher
Jul 10, 2025

ArriVent BioPharma stock rating resumed at Buy by Goldman Sachs - Investing.com Canada

Jul 10, 2025
pulisher
Jul 08, 2025

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering - Mintz

Jul 08, 2025
pulisher
Jul 03, 2025

ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval - Investing.com Canada

Jul 03, 2025
pulisher
Jul 03, 2025

ArriVent BioPharma Announces $75 Million Public Offering - The Globe and Mail

Jul 03, 2025
pulisher
Jul 02, 2025

Latham & Watkins Advises on ArriVent’s US$75 Million Common Stock Offering and Pre-Funded Warrants - Latham & Watkins LLP

Jul 02, 2025
pulisher
Jul 02, 2025

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Jul 02, 2025
pulisher
Jul 01, 2025

ArriVent BioPharma Plans $75 Million Public Offering - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

ArriVent BioPharma announces $75 million public offering By Investing.com - Investing.com UK

Jul 01, 2025
pulisher
Jul 01, 2025

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants - TradingView

Jul 01, 2025
pulisher
Jun 28, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jun 28, 2025

Arrivent Biopharma Inc Stock (AVBP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Cap:     |  Volume (24h):